VJOncology is committed to improving our service to you

ELCC 2017 | Data update in advanced stage NSCLC

VJOncology is committed to improving our service to you

Solange Peters

Solange Peters, MD, PhD, from the University of Lausanne, Lausanne, Switzerland discusses the ongoing clinical trials investigating advanced stage non-small cell lung cancer (NSCLC) at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland. Dr Peters provides insight into the design of the ETOP 6-14 NICOLAS trial (NCT02434081), investigating the addition of the anti-PD-1 agent, nivolumab, to standard first-line chemotherapy and radiotherapy. Making comparisons to the PACIFIC (NCT02125461) trial, evaluating the anti-PD-L1 agent, durvalumab following concurrent chemoradiation therapy, Dr Peters shares the latest results from both trials.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter